Avoro Capital Advisors’s Indaptus Therapeutics INDP Stock Holding History

Avoro Capital Advisors’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-366	Closed	-$3.56M	–	35
2019 Q2	$3.56M	Sell	366 -750	-67%	-$9.46M	0.12%	33
2019 Q1	$18.3M	Hold	1,116	–	–	0.79%	22
2018 Q4	$18.9M	Sell	1,116 -32	-3%	-$436K	1.13%	18
2018 Q3	$14.5M	Hold	1,148	–	–	0.67%	27
2018 Q2	$11.3M	Buy	1,148 +168	+17%	+$1.86M	0.44%	32
2018 Q1	$13.9M	Hold	980	–	–	0.67%	27
2017 Q4	$11.3M	Hold	980	–	–	0.73%	25
2017 Q3	$19.7M	Buy	+980	New	+$14.1M	1.52%	20

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Avoro Capital Advisors's INDP Position: Q3 2019 in Review

Avoro Capital Advisors sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 366 shares — an estimated $3.56M sold.

Avoro Capital Advisors first reported a position in INDP in Q3 2017 and held it in 8 quarters. The position peaked at $19.7M in Q3 2017. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

Avoro Capital Advisors reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
Avoro Capital Advisors sold 366 Indaptus Therapeutics shares in Q3 2019, an estimated $3.56M.
Avoro Capital Advisors first reported a position in Indaptus Therapeutics in Q3 2017 and held it in 8 quarters.
Avoro Capital Advisors's Indaptus Therapeutics position peaked at $19.7M in Q3 2017.
33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on Avoro Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.